Prognostic Significance of HLA Class I Expression in Ewing's Sarcoma Family of Tumors

被引:33
作者
Yabe, Hiroki [2 ]
Tsukahara, Tomohide
Kawaguchi, Satoshi [1 ]
Wada, Takuro
Torigoe, Toshihiko [3 ]
Sato, Noriyuki [3 ]
Terai, Chihiro [2 ]
Aoki, Masaya [4 ]
Hirose, Shigemichi [5 ]
Morioka, Hideo [6 ]
Yabe, Hiroo [6 ]
机构
[1] Sapporo Med Univ, Dept Orthopaed Surg, Sch Med, Chuo Ku, Sapporo, Hokkaido 0608543, Japan
[2] Jichi Med Univ, Div Rheumatol, Saitama Med Ctr, Saitama, Japan
[3] Sapporo Med Univ, Dept Pathol, Sch Med, Sapporo, Hokkaido 0608543, Japan
[4] Natl Sanat Tama Zenshoen, Div Clin Lab, Tokyo, Japan
[5] Keio Univ, Sch Med, Dept Diagnost Pathol, Tokyo, Japan
[6] Keio Univ, Sch Med, Dept Orthopaed Surg, Tokyo, Japan
关键词
Ewing's; sarcoma; ESFT; HLA class I; CD8; T lymphocyte; CHILDRENS-ONCOLOGY-GROUP; NEUROECTODERMAL TUMOR; MONOCLONAL-ANTIBODY; ANTIGEN-EXPRESSION; DOWN-REGULATION; POOR-PROGNOSIS; CELL CARCINOMA; CHEMOTHERAPY; IMMUNOTHERAPY; CANCER;
D O I
10.1002/jso.21829
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Ewing's sarcoma family of tumors (ESFT) is one of the most malignant groups of tumors in young people. Human leukocyte antigen (HLA) class I displays endogenously processed peptides to CD8+ T lymphocytes and has a key role for host immune surveillance. In ESFT, the investigation concerning both HLA class I expression and T-cell infiltration has yet to be reported. Methods: Biopsy specimens from 28 ESFT patients were evaluated by immunohistochemistry with the anti-HLA class I monoclonal antibody (mAb) EMR8-5 and anti-CD8 mAb, respectively. Results: Expression of HLA class I was negative in 10 tumors and down-regulated in 22 tumors. The status of CD8+ T cell infiltration was closely associated with the expression levels of HLA class I. ESFT patients with down-regulated or negative expression of HLA class I showed significantly poorer survival than the rest of the patients. Conclusions: Our results suggested that CD8+T cell-mediated immune response restricted by HLA class I might play an important role in immune surveillance of ESFT, and we revealed for the first time that the status of HLA class I expression affects the survival of the patients with ESFT. J. Surg. Oncol. 2011; 103: 380-385. (C) 2010 Wiley-Liss, Inc.
引用
收藏
页码:380 / 385
页数:6
相关论文
共 33 条
[1]   Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition [J].
Berghuis, Dagmar ;
de Hooge, Alfons S. K. ;
Santos, Susy J. ;
Horst, Danielle ;
Wertz, Emmanuel J. ;
van Eggermond, Marja C. ;
van den Elsen, Peter J. ;
Taminiau, Antonle H. M. ;
Ottaviano, Laura ;
Schaefer, Karl-Ludwig ;
Dirksen, Uta ;
Hooijberg, Erik ;
Mulder, Arend ;
Melief, Comelis J. M. ;
Egeler, R. Maarten ;
Schilham, Marco W. ;
Jordanova, Ekaterina S. ;
Hogendoorn, Pancras C. W. ;
Lankester, Arjan C. .
JOURNAL OF PATHOLOGY, 2009, 218 (02) :222-231
[2]   Ewing's sarcoma family of tumors: Current management [J].
Bernstein, Mark ;
Kovar, Heinrich ;
Paulussen, Michael ;
Randall, R. Lor ;
Schuck, Andreas ;
Teot, Lisa A. ;
Juergens, Herbert .
ONCOLOGIST, 2006, 11 (05) :503-519
[3]   Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric oncology group/children's cancer group phase II study 9457 - A report from the children's oncology group [J].
Bernstein, ML ;
Devidas, M ;
Lafreniere, D ;
Souid, AK ;
Meyers, PA ;
Gebhardt, M ;
Stine, K ;
Nicholas, R ;
Perlman, EJ ;
Dubowy, R ;
Wainer, IW ;
Dickman, PS ;
Link, MP ;
Goorin, A ;
Grier, HE .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (01) :152-159
[4]   Analysis of HLA class I alterations in tumors: choosing a strategy based on known patterns of underlying molecular mechanisms [J].
Cabrera, T. ;
Maleno, I. ;
Collado, A. ;
Nevot, M. A. Lopez ;
Tait, B. D. ;
Garrido, F. .
TISSUE ANTIGENS, 2007, 69 :264-268
[5]  
ENNEKING WF, 1986, CLIN ORTHOP RELAT R, P9
[6]   Adoptive immunotherapy for cancer: building on success [J].
Gattinoni, L ;
Powell, DJ ;
Rosenberg, SA ;
Restifo, NP .
NATURE REVIEWS IMMUNOLOGY, 2006, 6 (05) :383-393
[7]   Development of HLA-A2402/Kb transgenic mice [J].
Gotoh, M ;
Takasu, H ;
Harada, K ;
Yamaoka, T .
INTERNATIONAL JOURNAL OF CANCER, 2002, 100 (05) :565-570
[8]   Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone [J].
Grier, HE ;
Krailo, MD ;
Tarbell, NJ ;
Link, MP ;
Fryer, CJH ;
Pritchard, DJ ;
Gebhardt, MC ;
Dickman, PS ;
Perlman, EJ ;
Meyers, PA ;
Donaldson, SS ;
Moore, S ;
Rausen, AR ;
Vietti, TJ ;
Miser, JS .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (08) :694-701
[9]  
JAFFE N, 1976, CANCER-AM CANCER SOC, V38, P1925, DOI 10.1002/1097-0142(197611)38:5<1925::AID-CNCR2820380510>3.0.CO
[10]  
2-J